search
Back to results

Relative-dose-response Test (RDR) Adaptation for Chronic Liver Disease

Primary Purpose

Chronic Liver Disease

Status
Completed
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
retinyl palmitate (UNICEF, Melbourne, Australia)
Sponsored by
Universidade Federal do Rio de Janeiro
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Chronic Liver Disease focused on measuring chronic liver disease, cirrhosis, vitamin A, RDR test, retinol-binding protein

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • diagnosis of liver cirrhosis of viral etiology, alcoholic or metabolic action

Exclusion Criteria:

  • malabsorption syndromes
  • moderate or severe infection
  • diabetes mellitus using insulin renal, cardiac or respiratory
  • therapeutic doses of vitamin A in the 6 months prior to data collection

Sites / Locations

  • Gabriela Villaça Chaves

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

RDR test (1500 UI vitamin A)

RDR test (2500 IU vitamin A)

Arm Description

81 patients with several etiologies of liver cirrhosis at different stages in the progression of the disease received 1500 UI retinyl palmitate dosage at T0 (blood sample taken following a 12-hour fast). Following supplementation, we took further blood samples five and seven hours later (T5 and T7).

81 patients with several etiologies of liver cirrhosis at different stages in the progression of the disease received 2500 UI retinyl palmitate dosage at T0 (blood sample taken following a 12-hour fast). Following supplementation, we took further blood samples five and seven hours later (T5 and T7).

Outcomes

Primary Outcome Measures

Change from Baseline in retinol status (RDR test) at 5 and/or 7 hour after supplementation
Therapeutic response is evaluated by means of circulating serum retinol, 5 and 7 hours after the administration of vitamin A. The RDR was calculated by the following formula, using the values of serum retinol in the three times of blood collection (Loerch et al., 1979), expressed in percentages: RDR (%) = [(A0-Ax) / Ax] x100 where A0 is the serum retinol at time 0 (fasting) and Ax is the serum retinol 5 or 7 h after administration of vitamin A. It was used as the RDR cutoff ≥ 20%, indicating indirect hepatic reserve inadequate

Secondary Outcome Measures

serum retinol-binding protein (RBP)

Full Information

First Posted
June 25, 2012
Last Updated
July 2, 2012
Sponsor
Universidade Federal do Rio de Janeiro
search

1. Study Identification

Unique Protocol Identification Number
NCT01634698
Brief Title
Relative-dose-response Test (RDR) Adaptation for Chronic Liver Disease
Official Title
Responsiveness of RDR Test to Assess Hepatic Vitamin A Stores in Chronic Liver Disease
Study Type
Interventional

2. Study Status

Record Verification Date
May 2012
Overall Recruitment Status
Completed
Study Start Date
October 2007 (undefined)
Primary Completion Date
December 2007 (Actual)
Study Completion Date
December 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universidade Federal do Rio de Janeiro

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The relative-dose-response test (RDR) is considered to be the most accurate method for evaluating vitamin A nutritional status (VANS) in patients suffering from liver disease, as it infers the reserves of the vitamin in the liver. However, for the RDR test to reflect VANS in patients suffering from chronic liver disease, factors inherent to the disease need to be considered, such as possible malabsorption, advanced age, a drop in synthesis and/or the release of retinol binding protein (RBP), which would result in an inadequate response to the RDR test. Thus, the objective of present study is to assess the adequacy of two different protocol for using the RDR test in patients with cirrhosis and cirrhosis-related hepatocellular carcinoma. Methods: The sample group was comprised of 178 patients at Federal University of Rio de Janeiro University Hospital (111 men) with several etiologies of liver cirrhosis at different stages in the progression of the disease. They were sorted into two groups, according to the retinyl palmitate dosage (1500 IU or 2500 IU) received at T0 (blood sample taken following a 12-hour fast). Following supplementation, the investigators took further blood samples five and seven hours later (T5 and T7). The investigators assessed VANS via concentrations of serum retinol and RBP, as well as by way of the RDR test. The cutoff points the investigators used for denoting inadequacy in the indicators retinol and RDR were, respectively, < 1.05 µmol/L and ≥ 20%. To classify the degrees of severity of the disease the investigators used the criteria established by Child & Pugh (1973).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Liver Disease
Keywords
chronic liver disease, cirrhosis, vitamin A, RDR test, retinol-binding protein

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
178 (Actual)

8. Arms, Groups, and Interventions

Arm Title
RDR test (1500 UI vitamin A)
Arm Type
Experimental
Arm Description
81 patients with several etiologies of liver cirrhosis at different stages in the progression of the disease received 1500 UI retinyl palmitate dosage at T0 (blood sample taken following a 12-hour fast). Following supplementation, we took further blood samples five and seven hours later (T5 and T7).
Arm Title
RDR test (2500 IU vitamin A)
Arm Type
Experimental
Arm Description
81 patients with several etiologies of liver cirrhosis at different stages in the progression of the disease received 2500 UI retinyl palmitate dosage at T0 (blood sample taken following a 12-hour fast). Following supplementation, we took further blood samples five and seven hours later (T5 and T7).
Intervention Type
Dietary Supplement
Intervention Name(s)
retinyl palmitate (UNICEF, Melbourne, Australia)
Other Intervention Name(s)
vitamin A
Intervention Description
the patients received an oral dose of 1500 IU or 2500 IU, once.
Primary Outcome Measure Information:
Title
Change from Baseline in retinol status (RDR test) at 5 and/or 7 hour after supplementation
Description
Therapeutic response is evaluated by means of circulating serum retinol, 5 and 7 hours after the administration of vitamin A. The RDR was calculated by the following formula, using the values of serum retinol in the three times of blood collection (Loerch et al., 1979), expressed in percentages: RDR (%) = [(A0-Ax) / Ax] x100 where A0 is the serum retinol at time 0 (fasting) and Ax is the serum retinol 5 or 7 h after administration of vitamin A. It was used as the RDR cutoff ≥ 20%, indicating indirect hepatic reserve inadequate
Time Frame
RDR will be calculated for the two intervention groups (1500 or 2500 IU vitamin A), for the two moments of blood sampling, 5 and 7 hours after supplementation.
Secondary Outcome Measure Information:
Title
serum retinol-binding protein (RBP)
Time Frame
RBP were analyzed at baseline, 5 and 7 hours after supplementation as a variable that explain the appropriate response or failure to respond to the RDR test.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: diagnosis of liver cirrhosis of viral etiology, alcoholic or metabolic action Exclusion Criteria: malabsorption syndromes moderate or severe infection diabetes mellitus using insulin renal, cardiac or respiratory therapeutic doses of vitamin A in the 6 months prior to data collection
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gabriela V Chaves, PhD
Organizational Affiliation
Universidade Federal do Rio de Janeiro
Official's Role
Principal Investigator
Facility Information:
Facility Name
Gabriela Villaça Chaves
City
Rio de Janeiro
State/Province
RJ
ZIP/Postal Code
22010050
Country
Brazil

12. IPD Sharing Statement

Citations:
PubMed Identifier
21736776
Citation
Peres WA, Chaves GV, Goncalves JC, Ramalho A, Coelho HS. Vitamin A deficiency in patients with hepatitis C virus-related chronic liver disease. Br J Nutr. 2011 Dec;106(11):1724-31. doi: 10.1017/S0007114511002145. Epub 2011 Jun 8.
Results Reference
result

Learn more about this trial

Relative-dose-response Test (RDR) Adaptation for Chronic Liver Disease

We'll reach out to this number within 24 hrs